PCMA appoints AdvaMed veteran J.C. Scott as CEO
Outgoing Pharmaceutical Care Management Association chief executive Mark Merritt is stepping down after 15 years.
Regulatory
With a nod from the FDA, Teva enters white-hot migraine market
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
Bigelow to succeed Kamp as head of Coalition for Healthcare Communication
John Kamp has served as the group’s executive director for 16 years.
Pfizer petitions FDA for biosimilar communications guidelines
The pharma company urged the government agency to take action on “misleading” communications about biosimilars.
Congress puts big price tag on innovation in pharma
It has become expensive to develop drugs — especially for specific mutations and small patient populations. But instead of helping pharma adapt, Congress is making innovation more costly.
FDA again reprimands Ascend Therapeutics for EstroGel promos that may mislead clinicians
Company draws its second untitled letter for material meant to plug the menopause brand to professionals.
PBMs see red in White House blueprint
The White House “healthcare blueprint” attempts to inject value into the U.S. healthcare system.
Experts split on impact of drug price hike freezes
Some of the world’s most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.
Focus turns to future after Right to Try Act passes
Congress has finally passed the Right to Try Act, but does it go far enough?
FDA wants clearer indications, usage language on product labels
The government agency released its latest guidance this week.
Want to read more?
Please login or register first to view this content.
